Gliadin as a stimulator of innate responses in celiac disease
- PMID:15829281
- DOI: 10.1016/j.molimm.2004.12.005
Gliadin as a stimulator of innate responses in celiac disease
Abstract
In celiac disease (CD) we have the prototype of an immune mediated response dominated by the activation of the adaptive immune system and in particular of CD4+ HLA class II restricted T cells. Various seminal studies have established the precise mechanism of how antigen (prolamine) specific activation of CD4+ mucosal T cells occurs. Thus, CD is a condition in which T cells and their activation is the essential hinge in the pathogenic process. These functional studies have provided the explanation for the genetic association between CD and certain HLA alleles (HLA DQ2 and DQ8). These genetic, molecular and functional studies have permitted the clarification of a powerful Th1 dominated pro-inflammatory response that characterises the small intestine of active CD patients. Despite this unassailable set of information and reports there are some intriguing points that have been raised by a series of studies which have indicated that CD is not only defined by an aberrant prolamine-induced activation of the adaptive immune system. New evidence and re-assessments of old studies, point to a more complex pathogenic cascade, which may help to unravel some of the residual obscure points of CD pathogenesis. Here, we outline the current concepts that indicate a direct involvement of the adaptive immune system and we discuss all the evidence supporting a direct activation of the innate immune system by fragments of prolamines, which are not recognized T cell epitopes and how they could influence CD. The gliadin-induced activation of the 'innate' immune system might also have a significant role in the induction and persistence of many CD complications and most definitively for the most aggressive one, namely mucosal T cell lymphomas. We further suggest a novel way to harness the unwanted immune response to toxic prolamine, and thus indicate new potential therapeutic strategies to treat or at least control CD.
Similar articles
- Adaptive and innate immune responses in celiac disease.Gianfrani C, Auricchio S, Troncone R.Gianfrani C, et al.Immunol Lett. 2005 Jul 15;99(2):141-5. doi: 10.1016/j.imlet.2005.02.017. Epub 2005 Apr 7.Immunol Lett. 2005.PMID:15876458Review.
- Molecular mechanisms of the adaptive, innate and regulatory immune responses in the intestinal mucosa of celiac disease patients.Diosdado B, Wijmenga C.Diosdado B, et al.Expert Rev Mol Diagn. 2005 Sep;5(5):681-700. doi: 10.1586/14737159.5.5.681.Expert Rev Mol Diagn. 2005.PMID:16149872Review.
- Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells.de Kauwe AL, Chen Z, Anderson RP, Keech CL, Price JD, Wijburg O, Jackson DC, Ladhams J, Allison J, McCluskey J.de Kauwe AL, et al.J Immunol. 2009 Jun 15;182(12):7440-50. doi: 10.4049/jimmunol.0900233.J Immunol. 2009.PMID:19494267
- Immunomodulatory strategies for celiac disease.Rossi M, Maurano F, Luongo D.Rossi M, et al.Int Rev Immunol. 2005 Sep-Dec;24(5-6):479-99. doi: 10.1080/08830180500371082.Int Rev Immunol. 2005.PMID:16318991Review.
- Celiac disease: from pathogenesis to novel therapies.Schuppan D, Junker Y, Barisani D.Schuppan D, et al.Gastroenterology. 2009 Dec;137(6):1912-33. doi: 10.1053/j.gastro.2009.09.008. Epub 2009 Sep 18.Gastroenterology. 2009.PMID:19766641Review.
Cited by
- Matrix expansion and syncytial aggregation of syndecan-1+ cells underpin villous atrophy in coeliac disease.Salvestrini C, Lucas M, Lionetti P, Torrente F, James S, Phillips AD, Murch SH.Salvestrini C, et al.PLoS One. 2014 Sep 8;9(9):e106005. doi: 10.1371/journal.pone.0106005. eCollection 2014.PLoS One. 2014.PMID:25198673Free PMC article.
- In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes.Zanoni G, Navone R, Lunardi C, Tridente G, Bason C, Sivori S, Beri R, Dolcino M, Valletta E, Corrocher R, Puccetti A.Zanoni G, et al.PLoS Med. 2006 Sep;3(9):e358. doi: 10.1371/journal.pmed.0030358.PLoS Med. 2006.PMID:16984219Free PMC article.
- Development of a Sequence Searchable Database of Celiac Disease-Associated Peptides and Proteins for Risk Assessment of Novel Food Proteins.Amnuaycheewa P, Abdelmoteleb M, Wise J, Bohle B, Ferreira F, Tetteh AO, Taylor SL, Goodman RE.Amnuaycheewa P, et al.Front Allergy. 2022 May 26;3:900573. doi: 10.3389/falgy.2022.900573. eCollection 2022.Front Allergy. 2022.PMID:35769554Free PMC article.
- Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease.Sánchez D, Palová-Jelínková L, Felsberg J, Simsová M, Pekáriková A, Pecharová B, Swoboda I, Mothes T, Mulder CJ, Benes Z, Tlaskalová-Hogenová H, Tucková L.Sánchez D, et al.Clin Exp Immunol. 2008 Sep;153(3):351-9. doi: 10.1111/j.1365-2249.2008.03701.x. Epub 2008 Jul 11.Clin Exp Immunol. 2008.PMID:18637103Free PMC article.
- The SPINK gene family and celiac disease susceptibility.Wapenaar MC, Monsuur AJ, Poell J, van 't Slot R, Meijer JW, Meijer GA, Mulder CJ, Mearin ML, Wijmenga C.Wapenaar MC, et al.Immunogenetics. 2007 May;59(5):349-57. doi: 10.1007/s00251-007-0199-5. Epub 2007 Feb 27.Immunogenetics. 2007.PMID:17333166Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials